Complementary Therapies and Cancer Treatment

Jeong Wook Kim

doi:10.5124/jkma.2008.51.5.427

Journal List > J Korean Med Assoc > v.51(5) > 1042022

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim: Complementary Therapies and Cancer Treatment

Focused Issue of This Month

Evidence-based Complementary and Alternative Medicine for Cancer

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2008; 51(5): 427-434.

Published online: 31 May 2008

DOI: https://doi.org/10.5124/jkma.2008.51.5.427

Complementary Therapies and Cancer Treatment

Jeong Wook Kim, M.D

Department of Internal Medicine, Chung-Ang University College of Medicine, Korea. ekg001@cau.ac.kr

Abstract

Many patients with cancer use complementary medicine that is used together with conventional medicine. The widespread use of complementary therapies in cancer patients has major implications for research and clinical practices. Some complementary therapies, such as polysaccharide K, Astragalus membranaceus and A. mistletoe, may offer therapeutic benefits for patients with cancer. However, others did not show significant clinical effects for cancer treatment. Therefore, it is important for physicians to communicate openly with cancer patients about the use of complementary therapy. In order to encourage open communications with their patients, physicians should be knowledgeable about the most commonly used remedies, or at least they should be able to direct patients to reliable sources of information.

Keywords: Complementary therapies, Neoplasm

Notes

This study was supported by a grant from the National R & D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(0720590).

References

1. Cassileth BR, Deng G. Complementary and alternative therapies for cancer. Oncologist. 2004. 9:80–89.

2. Verhoef MJ, Hilsden RJ, O'Beirne M. Complementary therapies and cancer care: an overview. Patient Educ Couns. 1999. 38:93–100.

3. Lee EI, Shin YC, Lee JH, Kim SD, Kim HJ, Jo MS. Use of complementary and alternative medicine in cancer patients at 7 general hospital in seoul. J Korean Public Health Assoc. 2002. 28:225–238.

4. Lee KS, Ahn HS, Hwang LI, Lee YS, Koo BH. Utilization of alternative therapies in cancer patients. J Korean Cancer Assoc. 1998. 30:203–213.

5. Borchers AT, Keen CL, Gershwin ME. Mushrooms, tumors, and immunity: an update. Exp Biol Med (Maywood). 2004. 229:393–406.

6. Ikekawa T, Nakanishi M, Uehara N, Chihara G, Fukuoka F. Antitumor action of some Basidiomycetes, especially Phllinus linteus. Gann. 1968. 59:155–157.

7. Nam SW, Han JY, Kim JI, Park SH, Cho SH, Han NI, Yang JM, Kim JK, Choi SW, Lee YS, Chung KW, Sun HS. Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol. 2005. 20:488–492.

8. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003. 32:201–215.

9. Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, Chan E, Koh HL, Li X, Zhou S. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food. 2005. 8:159–168.

10. Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI, Kim YW, Namkoong SE, Lee IP. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004. 14:589–594.

11. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002. 60:640–644.

12. Wu WC, Hsiao JR, Lian YY, Lin CY, Huang BM. The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line. Cancer Chemother Pharmacol. 2007. 60:103–111.

13. Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pacific J Allergy and Immunology. 2006. 24:33–45.

14. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007. 56:905–911.

15. Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y. Meta-Analysis Group of the Japanese Society for Cancer of the Colon Rectum. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2006. 55:404–411.

16. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, Kawashima M, Niibe H. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev. 1997. 21:71–77.

17. Nishiwaki Y, Furuse K, Fukuoka M, Ota M, Niitani H, Asakawa M, Nakai H, Sakai S, Ogawa N. A randomized controlled study of PSK combined immuno-chemotherapy for adenocarcinoma of the lung. Gan To Kagaku Ryoho. 1990. 17:131–136.

18. Block KI, Mead MN. Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003. 2:247–267.

19. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM Jr. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006. 24:419–423.

20. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005. 1:CD004540.

21. Suh SO, Kroh M, Kim NR, Joh YG, Cho MY. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med. 2002. 30:483–494.

22. Kim JP, Yoo HY, Yu HJ, Yang HK. The Effect of Ginseng on the Nutritional Status and the Immune Functions after Curative Operations on Gastric Carcinoma Patients. J Korean Surg Soc. 1998. 54:854–862.

23. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol. 2006. 163:645–653.

24. Ostrander GK, Cheng KC, Wolf JC, Wolfe MJ. Shark cartilage, cancer and the growing threat of pseudoscience. Cancer Res. 2004. 64:8485–8491.

25. Lu C, Lee JJ, Komaki R, Herbst RS, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong M, Fisch MJ. A phase III study of AE-941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non- small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2007. 18S:In : 2007 ASCO Annual Meeting Proceedings Part I; June 20 S; 7527.

26. Escudier B, Venner P, Buckowski R, Szczylik C, Oudard S, Champagne P, Hariton C, Dupont E. Phase III trial of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Proc Am Soc Clin Oncol. 2003. 22. (abstr 844).

27. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP. North Central Cancer Treatment Group. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005. 104:176–182.

28. Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology? Best Pract Res Clin Gastroenterol. 2003. 17:711–724.

29. Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Iguchi A, Kinukawa N. Kyushu University Urological Oncology Group. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol. 2008. 179:485–490.

30. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007. 12:103–119.

31. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001. 7:57–66.

32. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood). 2002. 227:920–923.

33. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W. North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007. 69:289–294.

34. Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R Jr, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006. 67:1257–1261.

35. Huang DB, Ran RZ, Yu ZF. Effect of Acanthopanax senticosus injection on the activities of human tumor necrosis factor and natural killer cell in blood in the patients with lung cancer. Zhongguo Zhong Yao Za Zhi. 2005. 30:621–624.

36. Wang D, Xia M, Cui Z, Tashiro S, Onodera S, Ikejima T. Cytotoxic effects of mansonone E and F isolated from Ulmus pumila. Biol Pharm Bull. 2004. 27:1025–1030.

37. Fang HL, Lin HY, Chan MC, Lin WL, Lin WC. Treatment of chronic liver injuries in mice by oral administration of ethanolic extract of the fruit of Hovenia dulcis. Am J Chin Med. 2007. 35:693–703.

38. Hong SH, Seo SH, Lee JH, Choi BT. The aqueous extract from Artemisia capillaris Thunb. inhibits lipopolysaccharide-induced inflammatory response through preventing NF-kappaB activation in human hepatoma cell line and rat liver. Int J Mol Med. 2004. 13:717–720.

TOOLS

Similar articles